The UK’s new decentralised manufacturing framework

The new Decentralised Manufacturing Framework came into force on 23 July 2025. It enables the production of innovative medicines products such as cellular therapies close to the patients who will receive them. The framework covers both Point of Care manufacturing and Modular Manufacturing, and it requires prior authorisation and provides an alternative to traditional, centralised productions

"E.I.P.G. is a European association representing the national, professional organizations of pharmacists
employed in the pharmaceutical or allied industries of the Member States of the European Union,
the European Economic Area, or European countries having a mutual recognition agreement
with the European Union on compliance control of regulated medicines."

Read More

Presentations

Our media library contains an extensive collection of presentations by EIPG Bureau members or delegates, and presentations made at Scientific Symposia.
Read More
Read More

Position Papers

EIPG issues comments and feedback in response to consultation documents and white papers released by the European Medicines Agency and the European Commission.
Read More
Read More

Education

EIPG’s initiatives dedicated to industrial pharmacist education, including the EU-funded projects MOGLYNET, PHAR-IN and PHARMINE.
Read More
Read More

Members’ Area

Member organisations can sign in here to get even more information regarding EIPG’s projects and works.
Read More

The challenging roadmap to design the future of EU’s R&D

The ongoing debate on simplifying and standardising the rules for accessing EU research funding is in an hot phase. ERC president Maria Leptin rejected the Commission’s proposals, while the ERC Scientific Council published its new rules for the evaluation of scientific proposals. In a recent speech on the advancement of the Competitiveness Compass, Mario Draghi emphasised the need for a more proactive approach to priority programmes on critical technologies. He also drew attention to dual-use technologies, an approach combining civil and defence applications which has divided the EU Parliament
Read More

Piero Iamartino Appointed as Executive Director of the EIPG

Piero Iamartino, a long-standing leader within EIPG and former President of the association, has been appointed Executive Director effective 1 October 2025. With more than two decades dedicated to advancing the role of industrial pharmacists in Europe, he will now guide the implementation of EIPG’s strategic plan and support the organisation in addressing the technological and regulatory challenges shaping the future of the pharmaceutical sector.
Read More

Consultation open on the revision of GMP’s Chapter 1

Comments on the draft revision of Chapter 1 of the Good Manufacturing Practices must be submitted by 3 December 2025. The revision aims to update this fundamental text in light of the more recent advancements in pharmaceutical manufacturing, so to better ensure the ef-fectiveness and safety of medicinal products. The EIPG will liaise with member associations to submit a joint response to the draft text.
Read More

The EU Commission’s Study on the deployment of AI in healthcare

The DG Santé published in August 2025 a very detailed study on issues to be solved to ensure the swift implementation of artificial intelligence in healthcare. The study provides a thorough analyses of the current deployment of AI systems from technical, clinical, regulatory and societal perspectives, offering suggestions on how to address open issues
Read More

Latest EMA’s updates on the use of RWE in regulatory decision-making

The third annual report on the integration of real-world evidence (RWE) into regulatory decision-making shows a marked increase in the number of RWE studies conducted by the three pathways for generating RWE, the European consortium DARWIN EU, the framework contract (FWC), and in-house EMA studies. The PRAC Committee gave rise to the higher number of requests in the monitored period
Read More